Caribou Biosciences, Inc. Cash and Restricted Cash
Caribou Biosciences, Inc. (CRBU) had Cash and Restricted Cash of $26.19 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $26.19M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $12.10M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $12.41M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $11.19M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $26.19M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $12.10M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $12.41M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $11.19M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $25.25M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $29.46M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $16.34M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $32.02M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $37.91M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $49.45M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $51.21M 10-K · filed 2026-03-05 |
| 2023-09-30 | $104.10M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $66.24M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $52.79M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $58.38M 10-K · filed 2025-03-10 |
| 2022-09-30 | $82.13M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $112.19M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $147.68M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $240.47M 10-K · filed 2024-03-11 |
| 2021-09-30 | $435.36M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $129.57M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $145.92M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $15.95M 10-K · filed 2023-03-09 |
| 2020-09-30 | $24.55M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $33.13M 10-Q · filed 2021-09-02 |
| 2019-12-31 | $41.07M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |